Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
2000 Turkeys
Roads, Travel and Traffic
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Jobs
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
2000 Turkeys
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Jobs
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Prothena Corporation plc - Ordinary Shares
(NQ:
PRTA
)
7.970
+0.080 (+1.01%)
Delayed Quote
Updated: 4:00 PM EST, Nov 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Prothena Corporation plc - Ordinary Shares
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Mid-Morning Market Update: Markets Open Higher; US Inflation Rate Rises To 7% In December
↗
January 12, 2022
Following the market opening Wednesday, the Dow traded up 0.56% to 36,453.49 while the NASDAQ rose 0.79% to 15,273.08. The S&P also rose, gaining, 0.60% to 4,741.45. The U.S....
Via
Benzinga
Best Stocks Of 2021: Meme Stocks, Biotechs Highlight Broad Sector Strength
↗
December 31, 2021
The list features stocks from diverse sectors as the economy recovers from the pandemic.
Via
Investor's Business Daily
7 Best Drug Stocks to Buy for 2022 Without Covid Catalysts
↗
December 07, 2021
These seven drug stocks, a mix of growth, value, and moonshot plays, each stand to see big moves in the next twelve months.
Via
InvestorPlace
Analyst Ratings For Prothena Corp
↗
November 19, 2021
Within the last quarter, Prothena Corp (NASDAQ:PRTA) has observed the follo...
Via
Benzinga
Expert Ratings For Prothena Corp
↗
September 30, 2021
Analysts have provided the following ratings for Prothena Corp (NASDAQ:PRTA
Via
Benzinga
Expert Ratings For Prothena Corp
↗
September 27, 2021
Analysts have provided the following ratings for Prothena Corp (NASDAQ:PRTA
Via
Benzinga
Expert Ratings For Prothena Corp
↗
September 17, 2021
Analysts have provided the following ratings for Prothena Corp (NASDAQ:PRTA
Via
Benzinga
7 A-Rated Biotechs to Buy for the Long Run
↗
December 03, 2021
The one thing the pandemic has shown us is biotechs are changing the way we treat diseases. These A-rated biotechs are great examples.
Via
InvestorPlace
Prothena Corp: Q3 Earnings Insights
↗
November 04, 2021
Prothena Corp (NASDAQ:PRTA) reported its Q3 earnings results on Thursday, November 4, 2021 at 04:00 PM. Here's what investors need to know about the announcement. Earnings...
Via
Benzinga
7 A-Rated Healthcare Stocks to Buy for the Long Haul
↗
November 01, 2021
It looks like we're on the back end of the Covid pandemic, so it's a good time to look at healthcare stocks that have a big future.
Via
InvestorPlace
What 8 Analyst Ratings Have To Say About Prothena Corp
↗
September 20, 2021
Analysts have provided the following ratings for Prothena Corp (NASDAQ:PRTA
Via
Benzinga
With Prothena Up Over 500% This Year, Is It Too Late to Get in?
↗
September 18, 2021
Promising drug candidates could lead to a best-in-class Alzheimer's treatment.
Via
The Motley Fool
Expert Ratings For Prothena Corp
↗
September 14, 2021
Within the last quarter, Prothena Corp (NASDAQ:PRTA) has observed the foll...
Via
Benzinga
What 9 Analyst Ratings Have To Say About Prothena Corp
↗
August 09, 2021
Analysts have provided the following ratings for Prothena Corp (NASDAQ:PRTA
Via
Benzinga
Where Prothena Corp Stands With Analysts
↗
July 19, 2021
Within the last quarter, Prothena Corp (NASDAQ:PRTA) has ...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021
↗
November 19, 2021
Upgrades Morgan Stanley upgraded the previous rating for EQT Corp (NYSE:
Via
Benzinga
Where Prothena Corp Stands With Analysts
↗
July 13, 2021
Prothena Corp (NASDAQ:PRTA) has observed the following an...
Via
Benzinga
The Daily Biotech Pulse: Cellect Jumps On First Apograft Transplantation, AstraZeneca, European Commission Bury Legal Hatchet, Cassava Defends Itself
↗
September 03, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 2) Abbott Laboratories (NYSE:...
Via
Benzinga
Return on Capital Employed Insights for Prothena Corp
↗
September 02, 2021
According to Benzinga Pro, during Q2, Prothena Corp (NASDAQ:PRTA) earned $27.95 million, a 187.04% increase from the preceding quarter. Prothena Corp also posted a total of $60.07...
Via
Benzinga
10 Biggest Price Target Changes For Monday
↗
August 09, 2021
Jefferies raised the price target on Tesla, Inc. (NASDAQ:
Via
Benzinga
The Daily Biotech Pulse: Merck Releases Twin Dose Of Positive Tidings, Astellas Voluntarily Pauses Gene Therapy Study, Ascendis Offering
↗
September 01, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 31) AC Immune SA (NASDAQ: ACIU...
Via
Benzinga
Recap: Prothena Corp Q2 Earnings
↗
August 05, 2021
Shares of Prothena Corp (NASDAQ:PRTA) rose in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 187.88% year over year to $0...
Via
Benzinga
Why Is Novo Nordisk Buying a Rare-Disease Candidate?
↗
July 24, 2021
The company is mainly known for its diabetes drugs but has some background in rare-disease drugs.
Via
The Motley Fool
The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical
↗
August 31, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26) Agenus Inc. (NASDAQ: AGEN)...
Via
Benzinga
10 Biggest Price Target Changes For Tuesday
↗
July 13, 2021
Wells Fargo lowered C.H. Robinson Worldwide, Inc. (NASDAQ:
Via
Benzinga
The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration
↗
August 27, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26) Agenus Inc. (NASDAQ: AGEN)...
Via
Benzinga
Topics
Intellectual Property
Mid-Afternoon Market Update: Dow Surges Over 100 Points; State Auto Financial Shares Jump
↗
July 12, 2021
Toward the end of trading Monday, the Dow traded up 0.34% to 34,987.02 while the NASDAQ rose 0.08% to 14,713.30. The S&P also rose, gaining 0.26% to 4,380.72. The U.S. has the...
Via
Benzinga
Topics
Stocks
Mid-Day Market Update: Crude Oil Down 1%; Celldex Therapeutics Shares Spike Higher
↗
July 12, 2021
Midway through trading Monday, the Dow traded up 0.28% to 34,967.12 while the NASDAQ rose 0.08% to 14,714.09. The S&P also rose, gaining 0.23% to 4,379.69. The U.S. has the...
Via
Benzinga
Topics
Stocks
Mid-Morning Market Update: Markets Mostly Higher; Novo Nordisk To Acquire Prothena's ATTR Amyloidosis Program
↗
July 12, 2021
Following the market opening Monday, the Dow traded up 0.32% to 34,981.25 while the NASDAQ fell 0.07% to 14,691.53. The S&P also rose, gaining 0.15% to 4,376.17. The U.S. has...
Via
Benzinga
Topics
Stocks
Novo Nordisk To Buy Prothena's ATTR Amyloidosis Program For Up To $1.2B
↗
July 12, 2021
Novo Nordisk A/S (NYSE: NVO) will acquire Prothena Corporation plc's (NASDAQ: PRTA) and clinical stage antibody PRX004 and broader ATTR amyloidosis...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at
/week.
Subscribe Today